Literature DB >> 12086973

M(3) muscarinic receptors mediate contraction of human urinary bladder.

Charlotte Fetscher1, Marina Fleichman, Martina Schmidt, Susanne Krege, Martin C Michel.   

Abstract

Since muscarinic receptors appear to be the physiologically most important control system for urinary bladder contraction, we have characterized the receptor subtype mediating contraction in response to the muscarinic agonist carbachol in the human bladder. Experiments were based on four antagonists, the non-selective atropine, the M(1)-selective pirenzepine, the M(2)-selective methoctramine and the M(3)-selective darifenacin. All antagonists yielded Schild-plots with a slope close to unity. The order of potency (atropine> or =darifenacin>pirenzepine>methoctramine) as well as the estimated antagonist affinities suggested that contraction of the human bladder occurs predominantly if not exclusively via the M(3) receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086973      PMCID: PMC1573406          DOI: 10.1038/sj.bjp.0704781

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

Review 1.  The overactive bladder.

Authors:  J J Wyndaele
Journal:  BJU Int       Date:  2001-07       Impact factor: 5.588

2.  The role of M(2)-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro.

Authors:  T Yamanishi; C R Chapple; K Yasuda; R Chess-Williams
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

4.  Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins.

Authors:  P Wang; G R Luthin; M R Ruggieri
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

Review 5.  Pharmacology of lower urinary tract smooth muscles and penile erectile tissues.

Authors:  K E Anderson
Journal:  Pharmacol Rev       Date:  1993-09       Impact factor: 25.468

6.  Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle.

Authors:  A Choppin; R M Eglen
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

7.  Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle.

Authors:  A Choppin; R M Eglen
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

8.  Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype.

Authors:  M Matsui; D Motomura; H Karasawa; T Fujikawa; J Jiang; Y Komiya; S Takahashi; M M Taketo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Characterization of the functional muscarinic receptors in the rat urinary bladder.

Authors:  P A Longhurst; R E Leggett; J A Briscoe
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

View more
  39 in total

Review 1.  Muscarinic receptors: what we know.

Authors:  Harriette M Scarpero; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

2.  [New pharmacological treatment concepts for overactive bladder].

Authors:  M C Michel
Journal:  Urologe A       Date:  2003-04-25       Impact factor: 0.639

Review 3.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

4.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

Review 5.  Pathophysiology of overactive bladder.

Authors:  Mai A Banakhar; Tariq F Al-Shaiji; Magdy M Hassouna
Journal:  Int Urogynecol J       Date:  2012-02-07       Impact factor: 2.894

6.  Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel.

Authors:  Abhilash Paily; Guiseppe Preziosi; Prateesh Trivedi; Anton Emmanuel
Journal:  Spinal Cord       Date:  2019-02-25       Impact factor: 2.772

7.  Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue.

Authors:  Melinda Wuest; Birgit Eichhorn; Manfred Braeter; Gerhard Strugala; Martin C Michel; Ursula Ravens
Journal:  Pflugers Arch       Date:  2007-12-21       Impact factor: 3.657

8.  The effects of reformulation: improved therapeutic index.

Authors:  Scott MacDiarmid; Bobby W Sandage; Bimal K Malhotra
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

Review 9.  The puzzle of overactive bladder: controversies, inconsistencies, and insights.

Authors:  Roger R Dmochowski
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-06-27

Review 10.  A benefit-risk assessment of extended-release oxybutynin.

Authors:  Martin C Michel
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.